TRIM16 and melanoma: These data demonstrate that combination therapy with C012 and vemurafenib had in vivo efficacy against melanoma cells and suggest that induction of TRIM16 may be a necessary component of the therapeutic effect in the Mel-JD BRAFWT/NRASQ61R melanoma subtype.